Llwytho...
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
The efficacy of standard antidepressants is limited for many patients with mood disorders such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent need to develop novel therapeutics. Both clinical and preclinical studies have implicated glutamatergic system dysfunction...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | CNS Drugs |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8201267/ https://ncbi.nlm.nih.gov/pubmed/33904154 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-021-00816-x |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|